Paul Mellett - Enanta Pharmaceuticals CFO and Sr. VP of Fin. and Admin.
| ENTA Stock | USD 6.44 0.14 2.22% |
CFO
Mr. Paul J. Mellett Jr. is Chief Financial Officer, Senior Vice President Finance Administration of the Company. From April 2001 through August 2003, he held the position of Senior Vice President and Chief Financial Officer of Essential Therapeutics, Inc., a publiclyheld biotechnology company. Previously, Mr. Mellett was the Chief Financial Officer and Vice President of Administration at GelTex Pharmaceuticals, Inc., a publicly held biotechnology company that was acquired by Genzyme Corporation in December 2000. From 1994 to 1997, Mr. Mellett served as Chief Financial Officer of Marshall Contractors, a construction management firm specializing in the pharmaceutical, biotechnology and semiconductor industries, which was acquired by Fluor Corporation in 1996. From 1977 to 1994, Mr. Mellett was employed with Deloitte Touche LLP, a public accounting firm, and was promoted to Audit Partner in 1989 since 2003.
| Age | 70 |
| Tenure | 22 years |
| Phone | 617 607 0800 |
| Web | https://www.enanta.com |
Paul Mellett Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paul Mellett against Enanta Pharmaceuticals stock is an integral part of due diligence when investing in Enanta Pharmaceuticals. Paul Mellett insider activity provides valuable insight into whether Enanta Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Enanta Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Enanta Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paul Mellett over six months ago Disposition of 2412 shares by Paul Mellett of Enanta Pharmaceuticals at 9.63 subject to Rule 16b-3 | ||
Paul Mellett over six months ago Acquisition by Paul Mellett of 10440 shares of Enanta Pharmaceuticals at 14.0 subject to Rule 16b-3 |
Enanta Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1775) % which means that it has lost $0.1775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.691) %, meaning that it created substantial loss on money invested by shareholders. Enanta Pharmaceuticals' management efficiency ratios could be used to measure how well Enanta Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts. Enanta Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 155 people. Enanta Pharmaceuticals (ENTA) is traded on NASDAQ Exchange in USA. It is located in 4 Kingsbury Avenue, Watertown, MA, United States, 02472 and employs 131 people. Enanta Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.Management Performance
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.18 |
Enanta Pharmaceuticals Leadership Team
Elected by the shareholders, the Enanta Pharmaceuticals' board of directors comprises two types of representatives: Enanta Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enanta. The board's role is to monitor Enanta Pharmaceuticals' management team and ensure that shareholders' interests are well served. Enanta Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enanta Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jay Luly, CEO and President and Director | ||
| Scott MD, Senior Officer | ||
| Nathalie MD, Consultant | ||
| Jennifer Viera, Executive Communications | ||
| Nathaniel JD, General VP | ||
| Tara Kieffer, Senior Development | ||
| Brendan Luu, Senior Development | ||
| Matthew JD, Chief Secretary | ||
| Paul Mellett, CFO and Sr. VP of Fin. and Admin. | ||
| Yat Or, Chief Scientific Officer and Sr. VP of RandD | ||
| Scott Rottinghaus, VP Officer |
Enanta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enanta Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (1.58) % | ||||
| Operating Margin | (1.39) % | ||||
| Current Valuation | (21.85 M) | ||||
| Shares Outstanding | 21.33 M | ||||
| Shares Owned By Insiders | 6.57 % | ||||
| Shares Owned By Institutions | 96.10 % | ||||
| Number Of Shares Shorted | 3.57 M | ||||
| Price To Earning | 366.13 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.